Translations:Glucagon-like peptide-1/24/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
 
(No difference)

Latest revision as of 09:48, 11 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Glucagon-like peptide-1)
== Research history ==
In the 1980s, [[Svetlana Mojsov]] worked on the identification of GLP-1 at [[Massachusetts General Hospital]], where she was head of a peptide synthesis facility. To try to identify whether a specific fragment of GLP-q was an incretin, Mojsov created an incretin-antibody and developed ways to track its presence. She identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Mosjov and her collaborators [[Daniel J. Drucker]] and Habener showed that small quantities of lab-synthesized GLP-1 could trigger insulin.

Research history

In the 1980s, Svetlana Mojsov worked on the identification of GLP-1 at Massachusetts General Hospital, where she was head of a peptide synthesis facility. To try to identify whether a specific fragment of GLP-q was an incretin, Mojsov created an incretin-antibody and developed ways to track its presence. She identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Mosjov and her collaborators Daniel J. Drucker and Habener showed that small quantities of lab-synthesized GLP-1 could trigger insulin.